A business and scientific leader in pharmaceutical and biotechnology R&D, Dr. Moore has devoted his 30-year career to championing new chemical entities from discovery to the clinic (navigating the pharmaceutical industry ‘Valley of Death’) for the treatment of asthma, osteoporosis, inflammatory diseases, and with an emphasis on oncology.  Before joining Propella in 2017, Dr. Moore held key positions of increasing responsibility at Merrell Dow Research Institute, Axys Pharmaceuticals, Locus Pharmaceuticals, Viamet Pharmaceuticals, and most recently at Innocrin Pharmaceuticals. At Innocrin, Dr. Moore led development activities for seviteronel, a lyase selective inhibitor of CYP17 enzyme, for the treatment of metastatic prostate cancer and advanced breast cancer.  Dr. Moore’s responsibilities have included corporate strategy, business development, management of external alliances, intellectual property strategy, fundraising, and all aspects of R&D and technology innovation.

Dr. Moore holds a BS in chemistry from Southeastern Massachusetts University, a PhD in chemistry from Brown University and, prior to joining the pharmaceutical industry, was a Winston Fellow and Assistant Professor in Biochemistry at Cornell University Medical College.

Dr. George Cox brings more than 30 years of combined science and legal experience to Propella Therapeutics. Prior to joining Propella, Dr. Cox was in private practice at IP & Business Law Counseling, LLC, Miles & Stockbridge PC, and Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.  Before attending law school, he enjoyed a career as a biomedical scientist and medical school professor at the National Cancer Institute and the Uniformed Services University of the Health Sciences. He’s authored more than 70 publications in diverse scientific disciplines including pharmacology, immunology, biochemistry, and cell and molecular biology.

Dr. Cox earned his BA degree in chemistry and zoology from Ohio Wesleyan University, his PhD degree in pharmacology from The Ohio State University College of Medicine, and his JD degree from The American University Washington College of Law.  Dr. Cox also serves on the Board of Directors of Luminary Therapeutics.

Brendan has spent the bulk of his career as an investment banker providing capital markets and advisory services to clients across North America, Europe, and Asia. Prior to joining Propella Therapeutics, he was a senior member of the biotechnology investment banking team at SVB Leerink. During his time at SVB Leerink, he completed over 100 transactions, including more than 20 IPOs. Brendan began his career focused on funding early-stage innovation as the financial officer for an R&D company headquartered in Durham, North Carolina. Brendan earned a Master of Business Administration degree from Carnegie Mellon University’s Tepper School of Business, a Master of Public Policy Management degree from Carnegie Mellon University’s Heinz School of Public Policy, and a B.S. from Elon University.

Dr. Matt Sharp brings more than 25 years of pharmaceutical product development experience to Propella Therapeutics.  Prior to joining Propella he was Senior Director of Chemistry, Manufacturing and Controls (CMC) at Innocrin Pharmaceuticals.  Previously, he held a number of positions of increasing responsibility with GlaxoSmithKline (GSK), most recently serving as U.S. Head of Process Robustness and 2nd Generation, Active Pharmaceutical Ingredients (APIs).  In these roles he was responsible for the development and manufacture of APIs as well as finished drug products.  He has extensive experience in the manufacturing of drug products, research and development, process development, cGMP manufacturing, analytical development and quality systems.

In preparation for his pharmaceutical career, Matt received a BSc degree in Chemistry from Sheffield City (England) Polytech, a MSc in Organic Chemistry from the University of Waterloo (Canada), a PhD in Organic Chemistry from the University of California, Irvine, and then trained as postdoctoral research fellow at the University of California, Berkeley.

Tim Warneke has more than 30 years of pharmaceutical development experience in clinical operations. These experiences range across large (Ciba-Geigy and Abbott Laboratories) to mid-size (King Pharmaceuticals) pharmaceutical companies and the world’s largest contract research organization (Quintiles, now IQVIA).  Tim has leveraged his expert knowledge of the Code of Federal Regulations, ICH Guidelines, Good Clinical Practice to provide operational excellence in support of numerous INDs and NDAs throughout his career. Operationally focused, he has been responsible for clinical study conduct across all phases of pharmaceutical development from single-center studies to large multi-national clinical trials over a wide array of therapeutic areas.  Tim began his career at Northwestern University in the Department of Community Health and Preventive Medicine coordinating the clinical activities of the landmark NHLBI funded CARDIA study from its initial year in 1983 to 1988.

Tim holds a BS in Education and MS in Exercise Physiology from Eastern Illinois University.

Jonathan brings to the Propella Team a strong history of operations and project leadership experience, including over a decade focused within the life sciences.  As a Project Manager, Jonathan has led cross-functional teams that successfully completed multiple pharmaceutical development programs, and has also overseen completion of large-scale master development projects.  Prior to joining Propella, Jonathan served in roles of increasing responsibility at specialty pharmaceutical firm BioDelivery Sciences International (BDSI), supporting their growth and evolution from R&D to a commercial stage company.  His broad responsibilities included corporate strategy and operations oversight, project and alliance management, outsourcing and procurement, finance operations, and budget development.  Prior to BDSI, Jonathan worked at PRA Health Sciences in roles that included partnership management, business development, and proposals. Jonathan began his career as a Project Manager for Toll Brothers, a leading national luxury homebuilder.

Jonathan earned a Master of Business Administration degree from Elon University’s Love School of Business and is a certified Project Management Professional (PMP®).  He also received dual BS degrees in Business Management and Accounting from Elon University.